grant

Clinical trial of DZ13 DNAzyme targeting c-Jun in subjects with Basal Cell Carcinoma - DISCovery (Oligonucleotide Inhibition of Skin Cancer) study [ 2011 - 2012 ]

Also known as: Novel therapeutic approach to Basal Cell skin cancer

Funded by National Health and Medical Research Council
Managed by The University of Sydney
Managed by University of Sydney
Provided by   National Health and Medical Research Council

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/1017707]

Researchers: Dr Eun-Ae Cho (Principal investigator)

Brief description Basal cell carcinoma (BCC) is the commonest skin cancer in Australia that is highly invasive. Surgical removal is its main treatment option but causes scarring and is impractical when there are multiple cancers. C-Jun, a molecule promoting cell growth is present in abnormally large amount in BCC compared to normal cells. Dz13 targets and destroys these molecules, killing cancer cells when injected into the tumour. Dz13 may hence become a more effective and aesthetic alternative of treating BCC.

Funding Amount $AUD 74,365.37

Funding Scheme NHMRC Postgraduate Scholarships

Notes Medical Postgraduate Scholarship

Click to explore relationships graph
Help

Related Organisations

Related People

Subjects
Clinical Sciences | Dermatology | Medical and Health Sciences | basal cell carcinoma | cancer research | cancer treatment | clinical patient management | molecular oncology | skin cancer |
Identifiers
Viewed: [[ro.stat.viewed]]
Saved to MyRDA Save to MyRDA